Transfusion Medicine Reviews
Volume 21, Issue 3 , Pages 223-236 , July 2007

The Evidence for the Use of Recombinant Human Activated Factor VII in the Treatment of Bleeding Patients With Quantitative and Qualitative Platelet Disorders

  • Man-Chiu Poon

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Man-Chiu Poon, MD, University of Calgary, Foothills Hospital, 1403-29th St NW, Calgary, Alberta, Canada, T2N 2T9.

References 

  1. Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion. 1997;37:624–630
  2. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–979
  3. Jacobs MR, Palavecino E, Yomtovian R. Don't bug me: the problem of bacterial contamination of blood components—Challenges and solutions. Transfusion. 2001;41:1331–1334
  4. Engelfriet CP, Reesink HW, Blajchman MA, et al. Bacterial contamination of blood components. Vox Sang. 2000;78:59–67
  5. Poon MC, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951–3953
  6. Poon MC, d'Oiron R, von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: Results of an international survey. J Thromb Haemost. 2004;2:1096–1103
  7. Jurlander B, Thim L, Klausen NK, et al. Recombinant activated factor VII (rFVIIa): Characterization, manufacturing, and clinical development. Semin Thromb Hemost. 2001;27:373–384
  8. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638–648
  9. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10:352–359
  10. Shirahata A, Kamiya T, Takamatsu J, et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol. 2001;73:517–525
  11. Berrettini M, Mariani G, Schiavoni M, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica. 2001;86:640–645
  12. Morrissey JH, Mutch NJ. Tissue factor structure and function. Hemostasis and thrombosis. In:  Colman RE,  Marder VJ,  Clowes AW, et al. editor. Basic principles and clinical practice. ed 5. Philadelphia: Lippincott Williams & Wilkins; 2006;p. 91–106
  13. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193
  14. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost. 1997;78:1463–1467
  15. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998;4:790–798
  16. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778
  17. Baudo F, Redaelli R, Caimi TM, et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res. 2000;99:21–24
  18. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95:1330–1335
  19. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa–dependent coagulation in hemophilia blood. Blood. 2002;99:923–930
  20. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547
  21. Butenas S, Brummel KE, Bouchard BA, et al. How factor VIIa works in hemophilia. J Thromb Haemost. 2003;1:1158–1160
  22. He S, Blomback M, Jacobsson EG, et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost. 2003;1:1215–1219
  23. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175–179
  24. Kjalke M, Ezban M, Monroe DM, et al. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001;114:114–120
  25. Galán AM, Tonda R, Pino M, et al. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion. 2003;43:885–892
  26. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost. 2005;3:742–751
  27. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor–induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest. 1996;98:863–874
  28. Poon M-C. Factor VIIa. In:  Michelson AA editors. Platelets. ed 2. Boston: Elsevier Science; 2006;p. 1251–1261
  29. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor–independent thrombin generation. Blood. 2003;101:1864–1870
  30. Niewiarowski S, Levy-Toledano S, Caen JP. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res. 1981;23:457–463
  31. McGregor L, Hanss M, Sayegh A, et al. Aggregation to thrombin and collagen of platelets from a Glanzmann thrombasthenic patient lacking glycoproteins IIb and IIIa. Thromb Haemost. 1989;62:962–967
  32. Osdoit S, Rosa J-P. Polymeric fibrin interacts with platelets independently from integrin aIIob3. Blood. 2001;98:518a;(suppl, abstr)
  33. Lisman T, Adelmeijer J, Heijnen HF, et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor–independent fibrin generation. Blood. 2004;103:1720–1727
  34. Soslau G, Class R, Morgan DA, et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem. 2001;276:21173–21183
  35. Hedner U, Bergqvist D, Ljungberg J, et al. Haemostatic effect of factor VIIa in thrombocytopenic rabbits. Blood. 1985;86:1043;(suppl 1, abstr)
  36. Tranholm M, Rojkjaer R, Pyke C, et al. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res. 2003;109:217–223
  37. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26:159–164(suppl 1)
  38. Brenner B, Hoffman R, Balashov D, et al. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: An audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost. 2005;11:401–410
  39. Gerotziafas GT, Zervas C, Gavrielidis G, et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol. 2002;69:219–222
  40. Waddington DP, McAuley FT, Hanley JP, et al. The use of recombinant factor VIIa in a Jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorhage. Br J Haematol. 2002;119:286–288
  41. Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol. 2003;120:909–910
  42. Virchis A, Hughes C, Berney S. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia. Hematol J. 2004;5:281–282
  43. Busani S, Marietta M, Pasetto A, et al. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost. 2005;93:381–382
  44. Barnes C, Blanchette V, Canning P, et al. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med. 2005;15:145–150
  45. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000;83:634–635
  46. Billio A, Morello E, Amaddii G, et al. Treatment of refractory thrombocytopenic bleeding with rFVIIa: a case report. Blood. 2002;100:83;(suppl 1, abstr)
  47. Watson H, Salamat A, Tait J, et al. Successful treatment of life threatening haemorrhage with rVIIa during autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Blood. 2002;100:78;(suppl 1, abstr)
  48. Hoffman R, Eliakim R, Zuckerman T, et al. Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukemia. J Thromb Haemost. 2003;1:606–608
  49. Culligan DJ, Salamat A, Tait J, et al. Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Bone Marrow Transplant. 2003;31:1183–1184
  50. De Fabritiis P, Dentamaro T, Picardi A, et al. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica. 2004;89:243–245
  51. Zulfikar B, Kayran SM. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis. 2004;15:261–263
  52. Osborne W, Bhandari S, Tait RC, et al. Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. Clin Lab Haematol. 2004;26:229–231
  53. Kurekci AE, Atay AA, Okutan V, et al. Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis. 2005;16:145–147
  54. Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol. 2006;81:218–219
  55. Sokolic V, Bukovic D, Fures R, et al. Recombinant factor VIIa (rFVIIa) is effective at massive bleeding after caesarean section—A case report. Coll Antropol. 2002;26:155–157(suppl)
  56. Zupancic-Salek S, Sokolic V, Viskovic T, et al. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol. 2002;108:162–163
  57. Dart BW, Cockerham WT, Torres C, et al. A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome. J Trauma. 2004;57:171–174
  58. Merchant SH, Mathew P, Vanderjagt TJ, et al. Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet Gynecol. 2004;103:1055–1058
  59. Thomas AE, Plews DE. Use of recombinant factor VIIa in platelet disorders—A single centre experience. Blood Coagul Fibrinolysis. 2001;12:A14
  60. Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis. 2005;16:287–290
  61. Minniti C, Weinthal J. Use of recombinant activated factor VII (rFVIIa) in two children with idiopathic thrombocytopenic purpura (ITP). Blood. 2001;98:62b;(suppl 1, abstr)
  62. Conesa V, Navarro-Ruiz A, Borras-Blasco J, et al. Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: A case report. Int J Hematol. 2005;81:75–76
  63. Klamroth R, Gottstein S, Landgraf H. Successful use of recombinant factor VIIa to prevent bleeding during major surgery in a patient with severe immune thrombocytopenia. Blood. 2002;100:77b;(suppl 1, abstr)
  64. Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complication following hematopoietic stem cell transplantation. J Thromb Haemost. 2005;3:1935–1944
  65. Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001;28:405–407
  66. Phelan JT, Broder J, Kouides PA. Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: A case report of bilateral uterine artery embolization. Am J Hematol. 2004;77:151–155
  67. Eller P, Pechlaner C, Wiedermann CJ. Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation–related gastrointestinal bleeding. J. Thromb. 2006;4:1
  68. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. [letter] Thromb Haemost. 1996;75:981–982
  69. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost. 1999;82:1778
  70. Robinson KL, Savoia H, Street AM. Thrombotic complications in two patients receiving NovoSeven. Haemophilia. 2000;6:349;(abstr)
  71. d'Oiron R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000;83:644–647
  72. Monte S, Lyons G. Peripartum management of a patient with Glanzmann's thrombasthenia using Thrombelastograph. Br J Anaesth. 2002;88:734–738
  73. vanBuuren HR, Wielenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci. 2002;47:2134–2136
  74. Almeida AM, Khair K, Hann I, et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121:477–481
  75. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis. 2003;14:187–190
  76. Caglar K, Cetinkaya A, Aytac S, et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol. 2003;20:435–438
  77. Bell JA, Savidge GF. Glanzmann's thrombasthenia proposed optimal management during surgery and delivery. Clin Appl Thromb Hemost. 2003;9:167–170
  78. Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol. 2004;125:95–96
  79. Kale A, Bayhan G, Yalinkaya A, et al. The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med. 2004;32:456–458
  80. Uzunlar HI, Eroglu A, Senel AC, et al. A patient with Glanzmann's thrombasthenia for emergent abdominal surgery. Anesth Analg. 2004;99:1258–1260
  81. Coppola A, Tufano A, Cimino E, et al. Recombinant factor VIIa in a patient with Glanzmann's thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment. Thromb Haemost. 2004;92:1450–1452
  82. Yilmaz BT, Alioglu B, Ozyurek E, et al. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol. 2005;26:843–845
  83. Dargaud Y, Bordet JC, Trzeciak MC, et al. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: Observations on the monitoring and the mechanism of action of this drug. Haematologica. 2006;91:17–20(suppl)
  84. Musso R, Cultrera D, Russo M, et al. Recombinant activated factor VII as haemostatic agent in Glanzmann's thrombasthenia. Thromb Haemost. 1999;82:621;(suppl, abstr)
  85. Devecioglu O, Unuvar A, Anak S, et al. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turk J Pediatr. 2003;45:64–66
  86. Ito K, Yoshida H, Hatoyama H, et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang. 1991;61:40–46
  87. Martin I, Kriaa F, Proulle V, et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti–glycoprotein IIb-IIIa antibodies. Br J Haematol. 2002;119:991–997
  88. Poon MC, Zotz R, Di MG, et al. Glanzmann's thrombasthenia treatment: A prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol. 2006;43:S33–S36
  89. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. [letter] Thromb Haemost. 1998;80:352
  90. Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol. 2005;84:816–822
  91. PozoPozo AI, Jimenez-Yuste V, Villar A, et al. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis. 2002;13:551–553
  92. Langendonck L, Appel IM. Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease. Pediatr Blood Cancer. 2005;44:676–678
  93. Fressinaud E, Sigaud-Fiks M, Le Boterff C, et al. Use of recombinant factor VIIa (NovoSeven) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease. Haemophilia. 1998;4:299;(abstr)
  94. Inagaki M, Mori T, Tsunematsu Y, et al. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: A case report. Blood Coagul Fibrinolysis. 2006;17:317–322
  95. Meijer K, Sieders E, Slooff MJ, et al. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII [letter]. Thromb Haemost. 1998;80:204–205
  96. Révész T, Arets B, Bierings M. Recombinant factor VIIa in severe uremic bleeding. [letter] Thromb Haemost. 1998;80:353
  97. Cervera JS, Mena-Duran AV, Piqueras CS. The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost. 2005;93:383–384
  98. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700–1708
  99. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899–909
  100. Sallah S, Isaksen M, Seremetis S, et al. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—A rebuttal. J Thromb Haemost. 2005;3:820–822
  101. O'connell NM, Perry DJ, Hodgson AJ, et al. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 2003;43:1711–1716
  102. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–785

PII: S0887-7963(07)00019-3

doi: 10.1016/j.tmrv.2007.03.003

Transfusion Medicine Reviews
Volume 21, Issue 3 , Pages 223-236 , July 2007

Article Tools

* Image Usage & Resolution